566
Participants
Start Date
December 31, 2005
Primary Completion Date
February 29, 2008
Study Completion Date
February 29, 2008
etanercept
50 mg
sulphasalazine (SSZ)
Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
Doha
Heidelberg West
Debrecen
Nyíregyháza
Odense
Shenton Park
Kolding
Innsbruck
Szeged
Vejle
Pécs
Győr
Riyadh
Berlin
Marseille
Córdoba
Solna
Bergamo
Madrid
Madrid
Toulouse
Asturias
Bordeaux
Tampere
Santa Cruz de Tenerife
Reggio Emilia
Nantes
Orléans
Florence
Prato
Ostra Kyrkogardsgatan
Wiesbaden
Kuopio
Pierre Mendès
Amiens
Benevento
Potenza
Boulogne-Billancourt
Créteil
Beijing
Shanghai
Klagenfurt
Linz
Ostrava
Prague
Frederiksberg
Helsinki
Berlin
Erlangen
Gommern
Hamburg
Herne
Heubnerweg
Hildesheim
München
Pirna
Ratingen
Wiesbaden
Wilton
Dublin
Monserrato
Roma
Roma
Amsterdam
Groningen
Leeuwarden
Maastricht
Nijmegen
Lodz
Ustron Zawodzie
Warsaw
Wroclaw
Granollers
Barcelona
Porto
Upton
Basingstoke
Cambridge
Cannock
Glasgow
Liverpool
Newcastle upon Tyne
Upper Borough Walls
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY